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Background: Chronic non-cancer pain (CNCP) is a major health concern. Opioids may be a useful 
treatment option, but their use still remains controversial given the significant risks and epidemic of 
opioid addiction and abuse. There is limited data on whether opioid therapy is an effective treatment 
option for chronic non-cancer pain.  
Objective: To assess both physical and emotional dimensions of health for patients on opioid therapy 
for CNCP by reviewing the 36-Item Short Form Health Survey (SF-36) .
Study Design: This study was a retrospective cohort review.
Setting: Outpatient pain clinic
Methods: We recruited 182 patients at the West Penn Pain Institute outpatient pain clinic: 94 patients 
were recruited for the low-dose opioid group (5-30 morphine milligram equivalents [MME]) while 88 
patients were recruited for the high-dose opioid group (> 90 MME). Each patient filled out the SF-36 
survey used to assess both the physical and emotional dimensions of their health. We also analyzed 
patients’ employment status, reasons for unemployment, pain diagnosis, side effects, and compliance 
issues through the electronic medical record (EMR).
Results: Mean scores on General Health Perceptions for the low-dose and high-dose opioid groups were 
50.3 ± 21.6 and 44.4 ± 21.9, respectively (P = .07). Though not reaching statistical significance, high-
dose patients had lower item scores, indicating a perception of poorer health. There were no significant 
differences between the low-dose and high-dose opioid treatment groups on any of the mean scores 
from the 8 domains of the SF-36.  
There was a statistically significant association between opioid treatment group and working status, 
noncompliance, and the self-reported number of side effects. Patients treated with high-dose opioids had 
significantly higher rates of unemployment (85%) than did low-dose opioid patients (66%) (χ2[1] = 8.48, P 
=.004; odds ratio [OR] = 2.89 [95% confidence interval (CI), 1.39-6.01]). Unemployed patients in the high-
dose treatment group were more likely to list disability as unemployment while retirement was the most 
common response in the low-dose treatment group. Patients treated with high-dose opioids had significantly 
higher rates of self-reported side effects (46%) than did low-dose opioid patients (21%) (χ2[1] = 12.02, P 
=.001; OR = 3.08 [95% CI, 1.61-5.89]). Patients treated with high-dose opioids had significantly higher rates 
of noncompliance (49%) than did low-dose opioid patients (33%) (χ2[1] = 4.75, P =.029; OR = 1.94 [95% 
CI, 1.07-3.54]). Thus, the odds of a high-dose opioid patient being unemployed were 2.89 times greater than 
the odds for a low-dose opioid patient; the odds of a high-dose opioid patient self-reporting side-effects were 
3.08 times greater than the odds for a low-dose opioid patient; and the odds of a high-dose opioid patient 
being noncompliant with their medications were 1.94 times greater than the odds for a low-dose opioid 
patient. 
Limitations: The observation al design prohibits drawing causal relationships, and entry criteria was 
restricted.
Conclusions: These data suggest that patients receiving low-dose and high-dose opioid treatment do 
not have significantly different quality-of-life outcomes. Future studies that incorporate longitudinal data 
are necessary to examine the temporal relationship between quality of life and opioid therapy. 
Key words: Chronic pain, chronic non-cancer pain, opioids, pain, quality of life, side effects, 
noncompliance, unemployment
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need an increased dose of opioids in order to achieve 
a level of pain alleviation comparable to that initially 
achieved. For instance, a prospective cohort study by 
Campbell et al found that patients taking higher-dose 
opioids were more likely to have higher pain scores 
than patient groups taking lower-dose opioids, which 
may provide some explanation for the phenomenon of 
tolerance. A prospective study by Chu et al found that 
patients may have developed tolerance to morphine 
only after one month of use (4).
Another major concern about high-dose opioid 
therapy for CNCP is regarding aberrant drug behavior. 
Morasco et al performed a retrospective cohort study to 
compare patients on high-dose opioids and traditional-
dose opioid therapy. Patients in the high-dose opioid 
group were more likely to have more medical visits, 
attempt an opioid taper, receive a urine drug screen, 
and develop a pain goal than the traditional opioid 
dose group (1). This may suggest that patients receiving 
high-dose opioid therapy may be at less risk of aber-
rant drug behavior than originally thought. However, 
a prospective cohort study by Campbell et al found 
conflicting results; patients taking higher-dose opioids 
were more likely to have aberrant drug behavior (5).
There is also concern that opioid use may lead to 
a decline in a patients’ mental health and lead to func-
tional impairment. A retrospective study by Huffman 
et al found that patients weaned from opioid therapy 
after one year showed improvement in depression and 
anxiety and were less likely to be functionally impaired 
(6). A randomized control study by Kidner et al showed 
that patients taking higher dose of opioids were more 
likely to not return to work, become unemployed, and 
to be receiving social security disability insurance (7). 
The current literature has suggested variable and 
conflicting results regarding the social and functional 
implications of chronic opioid therapy for CNCP. This 
study aims to provide further research regarding the 
effectiveness of high-dose opioid therapy and compare 
it to low-dose opioids for CNCP. 
Methods
Study Design and Setting
The Institutional Review Board (IRB) at Allegheny 
Health Network provided approval for this study. We 
did a retrospective cohort study of patients being 
treated at the West Penn Pain Institute for chronic 
non-cancer pain with opioids between June 2016 and 
June 2018. The West Penn Institute is an outpatient 
Chronic pain is defined as pain that persists beyond the normal tissue healing time of 3 months. When chronic pain is not associated 
with cancer or end-of-life care, it is often referred to as 
“chronic non-cancer pain” (CNCP). CNCP is a prevalent 
health problem and accounts for a large proportion of 
health care expenditures. In addition, it is the leading 
cause of disability and can have a major influence on 
the patient in terms of quality of life, mental health, 
relationships, and employment. Opioids are one of the 
most potent analgesics available. They have a large role 
in the surgical setting and acute pain, but their use as 
a treatment option for chronic pain – specifically CNCP 
– remains controversial given the significant risks and 
given an epidemic of opioid addiction and abuse. There 
is limited data about the long-term effectiveness of 
opioids in regard to a patient’s physical and emotional 
health, specifically their functional health, well-being, 
psychometrically-based physical health, and mental 
health. There are also concerns about opioid tolerance, 
their side-effect profile, and anxiety over disapproval 
by regulatory bodies. These concerns are heightened 
for patients prescribed high doses of opioids. Despite 
this, the use of opioids for chronic non-cancer pain 
has increased substantially since the 1990s. High-dose 
opioid therapy occurs in 2% to 3% of patients with 
CNCP or low-back pain and among 8% of patients 
prescribed chronic opioid therapy (1). There is limited 
research evaluating the effectiveness of high-dose 
opioid therapy and its consequences for patients with 
CNCP, especially in comparison with low-dose opioid 
treatment.
High-dose opioid use can also lead to hyperalgesia, 
a form of central sensitization in which a patient’s pain 
level increases in parallel with elevation of his or her 
opioid use. A retrospective study looked at 23 patients 
undergoing detoxification from high-dose opioids for 
chronic pain. Of those 23 patients, 21 reported a signifi-
cant decrease in pain score after detoxification, which 
may provide some evidence for the phenomenon of 
hyperalgesia (2). A similar phenomenon of pain reduc-
tion after discontinuation of opioid medications was 
also examined by Sjogren et al. They reported 4 cases of 
cancer patients who developed hyperalgesia while on 
morphine. The hyperalgesia resolved after morphine 
withdrawal or opioid substitution (3). 
One of the major reasons why chronic dose opioid 
therapy is controversial is concern about developing tol-
erance. This often occurs in patients maintained on opi-
oids over a prolonged period. As a result, patients will 
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pain clinic in Pittsburgh affiliated with the 
teaching hospital of the Allegheny Health 
Network. Patients are treated with a medical 
team consisting of nurses, residents, fellows, 
and attending physicians.
Eligibility Criteria
The study cohort consisted of patients 
between the ages of 18 and 80 who had 
been suffering from a pain condition for at 
least 3 years. Patients were excluded if they 
had a concurrent diagnosis of cancer, did not 
speak or understand English, were deemed 
to be noncompliant, or were receiving end-
of-life care. After they were deemed eligible 
for the study, each patient’s current opioid 
therapy was examined through the Pennsyl-
vania Drug Monitoring Program (PDMP). The 
PDMP is a statewide program that collects 
information about controlled substance pre-
scription drugs that are dispensed to patients 
within the state and surrounding states. Pa-
tients were divided into 2 groups based on 
daily oral morphine milligram equivalents 
(MME). Patients were placed into the low-
dose opioid group if their opioid usage was 
between 5-30 MME; they were placed in the 
high-dose opioid group if their opioid usage 
was equal to or greater than 90 MME. Daily 
oral MME doses for the opioids taken by the 
cohort were estimated following review and 
synthesis of a range of clinical guidelines (8). 
Patients with MME between these 2 groups 
were not included for the purpose of this 
study. After obtaining written informed con-
sent, patients were recruited into the study.
Quality of Life Measures 
Quality of life was measured through 
the 36-Item Short Form Health Survey Instru-
ment (SF-36) survey. All patients were given 
the SF-36 at the time of visit to the clinic. 
The SF-36 measures 8 health concepts (also 
referred to as domains): physical functioning, 
bodily pain, role limitations due to physi-
cal health problems, role limitations due to 
personal or emotional problems, emotional 
well-being, social functioning, energy/fa-
tigue, and general health perceptions (9). 
These domains measure 3 aspects of health – 
functional status, well-being, and “overall evaluation of health” 
(10). The domains can also provide a summary of both physical 
and emotional quality of life. It has been validated, is used widely 
across medical disciplines, and can be self-administered by the pa-
tient with reliability. The SF-36 has been implemented to define 
disease conditions, to determine the effect of treatment, and to 
differentiate the effects of different treatments (11).
A single question is also included in the survey that gauges 
perceived change in health from the prior year. Interpretation of 
the SF-36 scores is based on the mean (average) scores of patients 
(12). All items are scored on a scale of 0 to 100 so that a high score 
defines a more favorable health state. Items that are left blank 
(missing data) are not taken into account when calculating the 
scale scores (8). Figure 1 shows the 8 domains of the SF-36 and the 
percentage contribution of each domain to the survey. 
Demographic Data
The following demographic data were obtained through 
careful review of the patient’s electronic medical record (EMR): 
age, body mass index (BMI), gender, pain diagnosis, complica-
tions, and side effects. In addition, employment status and rea-
son for unemployment were obtained through interview of the 
patient at the time of their visit of clinic.
Statistical Methods
Data analysis began with assessment of the normality of con-
tinuous variables using the Kolmogorov-Smirnov test. Continuous 
Fig. 1. Eight domains of  the SF-36 and Percentage Contribution to the 
Survey
Pain Physician: July/August 2019: 22:401-411
404  www.painphysicianjournal.com
and normally distributed data are reported as means 
and standard deviations; nonnormally distributed 
data are reported as median with interquartile range 
(IQR). Categorical variables are reported as counts and 
percentages. The independent samples t test or Mann-
Whitney test was used to compare continuous variables 
between the low-dose and high-dose opioid treatment 
groups. The chi-square test was used to compare cate-
gorical variables between groups. Odds ratios (OR) with 
95% confidence intervals (CI) are reported when the 
chi-square test was statistically significant. Cronbach’s 
alpha was used to assess the reliability of the SF-36. A 
value of P < .05 on 2-tailed testing was considered sta-
tistically significant. Statistical analyses were performed 
using SPSS Version 24.0 (IBM Corporation, Armonk, NY).
Results
A total of 182 patients who received treatment 
with opioids for the relief of non-cancer pain were 
analyzed. The mean patient age was 59.3 ± 13.0 years 
(range, 23-94 years) and 65.4% of the patients were 
women. The median BMI was 30.2 kg/m2 (IQR = 8.4).
Patients were divided into groups based on their 
opioid treatment dose. There was a slightly higher 
proportion of patients receiving low-dose opioids com-
pared with high-dose opioids (52% vs 48%). All patients 
were given the SF-36 to complete posttreatment. 
The 2 opioid treatment groups did not differ 
significantly in the baseline characteristics of age (P 
= .99), BMI (P = .15) or gender (P = .08); however, in 
both treatment groups, patients were more likely to be 
women (65.4%) than men (34.6%), and more women 
were in the low-dose opioid treatment group (71.3%) 
compared to the high-dose group (59.1%). The baseline 
characteristics of the patients are reported in Table 1. 
When the high-dose and low-dose opioid treat-
ment groups were compared on 6 common diagnoses 
(e.g., leg pain, leg + hip pain, hip pain (only), back pain, 
neck + head pain, peripheral pain, and all other pain 
not falling into the previous categories), the groups 
did not differ significantly on the number of reported 
diagnoses (P = .85).
Seventy-five percent of the study patients com-
pleted the SF-36; completion rates did not differ sig-
nificantly between the low-dose and high-dose opioid 
treatment groups (73% vs. 76%, P = .67). Although 
completion of the SF-36 was not significantly related to 
the baseline characteristics of opioid dosage, gender (P 
= .27), or BMI (P = .88), there was a significant difference 
in completion rates of the SF-36 by patient age. Patients 
who did not complete the form were significantly older 
than patients who did complete the form (62.2 ± 13.5 
years [n = 46] vs 58.2 ± 12.7 years [n = 136]; t[180] = 
-1.998, P = .047 [95% CI, -8.765 to -0.55]). 
There was a statistically significant association 
between opioid treatment group and working status, 
noncompliance, and the self-reported number of side 
effects (Table 2).  Patients treated with high-dose opioids 
had significantly higher rates of unemployment (85%) 
than did low-dose opioid patients (66%) (χ2[1] = 8.48, 
P =.004; OR = 2.89 [95% CI, 1.39-6.01]). Patients treated 
with high-dose opioids had significantly higher rates of 
self-reported side effects (46%) than did low-dose opioid 
patients (21%) (χ2[1] = 12.02, P = .001; OR = 3.08 [95% CI, 
1.61-5.89]). Patients treated with high-dose opioids had 
significantly higher rates of noncompliance (49%) than 
did low-dose opioid patients (33%) (χ2[1] = 4.75, P =.029; 
OR = 1.94 [95% CI, 1.07-3.54]). Thus, we can say that the 
odds of a high-dose opioid patient being unemployed 
were 2.89 times greater than the odds for a low-dose 
opioid patient; the odds of a high-dose opioid patient 
self-reporting side-effects were 3.08 times greater than 
the odds for a low-dose opioid patient; and the odds of a 
high-dose opioid patient being noncompliant with their 
Table 1. Baseline characteristics of  patients treated with low- vs high-dose opioids for  non-cancer pain (n = 182)*.
Variable 
Low-Dose
Opioid Group (n = 94)
High-Dose
Opioid Group (n = 88)
P Value
Age in yrs, mean ± SD 59.3 ± 13.1 59.3 ± 13.0 .99
BMI kg/m2, median (IQR) 30.6 (9.9) 29.9 (8.0) .15
Gender, n (%)
   Men 27 (28.7) 36 (40.9)
08
   Women 67 (71.3) 52 (59.1)
Abbreviations: BMI, body mass index; IQR, interquartile range; SD, standard deviation; SF-36, 36-Item Short Form Health Survey.
* Data are presented as mean ± SD, median (25%-75% IQR), or count (percentage).
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medications were 1.94 times greater than the odds for a 
low-dose opioid patient. 
A total of 135 patients (74.2%) reported that they 
were unemployed (not working) at the end of the 
treatment period. Of these 135 patients, 129 provided 
reasons for their unemployment. Responses were col-
lapsed into one of 3 categories: disability, retirement, 
and other. These categories included the most responses 
and made the data more meaningful for analysis. There 
was a statistically significant relationship between the 
reported reason for unemployment and opioid treat-
ment group (χ2[2] = 7.18, P =.03). Patients receiving 
high-dose opioids were more likely to report “disabil-
ity” as their reason for unemployment than patients 
receiving low-dose opioids (55.4% vs 34.4%). Patients 
receiving low-dose opioids were more likely to report 
“retirement” as their reason for unemployment (37.7% 
vs 20%). Table 3 summarizes this analysis (Table 4). 
A total of 60 patients (33%) reported side effects 
during the treatment period. Of these 60 patients, 
54 patients (90%) reported at least one complication 
that included constipation. Eighty-five percent of pa-
tients receiving low-dose opioid treatment reported 
at least one complication that included constipation, 
compared with 92.5% of patients receiving high-dose 
opioid treatment. There was no statistically significant 
association between opioid treatment group and the 
side-effect of constipation (P = .36). 
The low- and high-dose opioid patients did not dif-
fer significantly on their own rating of their perceived 
general health compared to one year earlier (49.2 ± 
23.9 vs 52.8 ± 24.7, P = .31). 
Table 5 summarizes the results of the SF-36 for each 
of the 8 domains. There were no significant differences 
between the low-dose and high-dose opioid treatment 
groups on any of the mean scores from the 8 domains 
of the SF-36. High-dose opioid patients scored higher 
(an indication of less disability or better quality of life) 
Table 2. Side effects and noncompliance in patients treated with low- vs  high-dose opioids for non-cancer pain (n = 182). Data are 
presented as count (percentage).
Variable
Low-Dose





Side Effects, n (%) n = 94 n = 88 .67
None 74 (78.7) 48 (54.5)
Constipation 15 (16) 26 (29.5)
Other 3 (3.2) 3 (3.4)
Constipation + other 2 (2.1) 11 (12.5)
Diagnoses, n (%) n = 94 (n = 87) .85
Leg pain 8 (8.5) 9 (10.3)
Leg + Hip pain 1 (1.1) 0
Hip pain (only) 5 (5.3) 4 (4.6)
Back pain 53 (56.4) 51 (58.6)
Neck + Head pain 12 (12.8) 9 (10.3)
Peripheral pain 7 (7.4) 3 (3.4)
All other pain not falling into the above categories 8 (8.5) 11 (12.6)
† A P value < .05 was considered statistically significant .
Table 3. Side effects and noncompliance in patients treated with low- vs high-dose opioids for non-cancer pain (n = 182). Data are 
presented as count (percentage).
Variable 





Side Effects, n (%) 20 (21.3) 40 (45.5) .001*
Noncompliance, n (%) 31 (33.0) 43 (48.9) .029*
† A P value < .05 was considered statistically significant .
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in only 2 domains, though not significantly: Role Limi-
tations – Emotional, and Emotional Well-Being. In the 
other 6 domains, low-dose opioid patients scored high-
er, though only General Health Perceptions approached 
significance. The Physical Functioning domain had the 
most missing responses (Table 6 and Fig. 2).
Mean scores on General Health Perceptions for 
the low-dose and high-dose opioid groups were 50.3 
± 21.6 and 44.4 ± 21.9, respectively (P = .07). Though 
Table 4. Reasons for unemployment in patients treated with low-dose vs high-dose opioids for non-cancer pain (n = 135) Data are 
presented as count (percentage).
Variable 





Reason for Unemployment†, n (%) (n = 55) (n = 74) .03*
   Disability 21 (38.2) 41 (55.4)
   Retired 23 (41.8) 15 (20.3)
   Other 11 (20) 18 (24.3)
# Data are presented as count (percentage).
† Of the 61 patients in the low-dose opioid group who indicated that they were unemployed, only 55 patients provided a reason for their unem-
ployment.
‡ A P value < .05 was considered statistically significant (*).
Table 5. Cronbach’s alpha and internal consistency for the 8 domains measured by the SF-36 in patients treated with low- vs high-dose 
opioids for non-cancer pain (n = 182).







Cronbach’s Alpha Internal Consistency Cronbach’s Alpha Internal Consistency 
Physical Functioning (n = 82) (n = 76)
.894 Good .918 Excellent 10
Role Limitations 
-Physical Health
(n = 90) (n = 83)
.849 Good .869 Good 4
Role Limitations 
-Emotional Health
(n = 91) (n = 81)
.828 Good .848 Good 3
Vitality, Energy, or 
Fatigue
(n = 90) (n = 83)
.826 Good .876 Good 4
Emotional Well-Being (n = 89) (n = 84)
.852 Good .850 Good 5
Social Functioning (n = 92) (n = 84)
.533 Poor .622 Questionable 2
Pain (n = 93) (n = 86)
.708 Acceptable .810 Good 2
General Health 
Perceptions
(n = 89) (n = 86)
.802 Good .818 Good 5
Abbreviations: SF-36, 36-Item Short Form Health Survey.
Table 5a. Interpretation of  Cronbach’s alpha
Cronbach's alpha Internal Consistency Reliability
.9 ≤ α Excellent
.8 ≤ α < .9 Good
.7 ≤ α < .8 Acceptable
.6 ≤ α < .7 Questionable
.5 ≤ α < .6 Poor
α < .5 Unacceptable
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not reaching statistical significance, high-dose pa-
tients had lower item scores, indicating a perception 
of poorer health. Figure 3 shows the mean scores for 
General Health Perceptions in patients treated with 
low- versus high-dose opioids for non-cancer pain. A 
poststudy sample size calculation indicated that 106 
patients would have been needed per group for the 
difference found in this domain to reach statistical 
significance. 
Cronbach’s alpha was used as a measure of internal 
consistency (“reliability”) of the SF-36 questionnaire. 
Internal consistency reliability describes the extent to 
which all the items in a test measure the same concept 
or construct; hence, it is connected to the interrelated-
ness of the items within the test. Cronbach’s alpha nor-
mally ranges between 0 and 1. The closer Cronbach’s 
alpha coefficient is to 1.0, the greater the internal 
consistency of the items in the scale (13). According to 
Table 6. Mean scores for the 8 domains of  the SF-36 in patients treated with low- vs high-dose opioids for non-cancer pain (n = 182)*
Variable
Low-Dose
Opioid Group (n = 94)
High-Dose
Opioid Group (n = 88)
P Value
Physical Functioning (n = 82) (n = 75)
   Mean ± SD 41.2 ± 24.4 38.9  26.3 .56
   Median (IQR) 35.0 (40.0) 40.0 (45.0) .49
Role Limitations –Physical Health (n = 90) (n = 83)
   Mean ± SD 30.8 ± 37.7 25.0  36.0 .30
   Median (IQR) 25.0 (50.0) 0 (50) .20
Role Limitations – motional (n = 91) (n = 81)
   Mean ± SD 45.4 ± 42.6 54.7  43.6 .16
   Median (IQR) 33.3 (100) 66.7 (100) .40
Vitality, Energy, or Fatigue (n = 90) (n = 83)
   Mean ± SD 40.7 ± 21.0 39.8  22.7 .79
   Median (IQR) 42.5 (30.0) 45.0 (35.0) .91
Emotional Well-Being (n = 89) (n = 84)
   Mean ± SD 64.7 ± 21.7 67.0  21.7 .49
   Median (IQR) 64.0 (38.0) 72.0 (28.0) .40
Social Functioning (n = 92) (n = 85)
   Mean ± SD 64.7 ± 24.0 63.4  26.4 .73
   Median (IQR) 62.5 (37.5) 62.5 (37.5) .95
Pain (n = 93) (n = 87)
   Mean ± SD 33.2 ± 19.0 29.9  20.5 .26
   Median (IQR) 32.5 (22.5) 22.5 (35.0) .28
General Health Perceptions (n = 89) (n = 86)
   Mean ± SD 50.3 ± 21.6 44.4  21.9 .07
   Median (IQR) 50.0 (30.0) 42.5 (30.0) .11
Health (Compared to Last Year) (n = 94) (n = 88)
   Mean ± SD 49.2 ± 23.9 52.8  24.7 .31
   Median (IQR) 50.0 (25.0) 50.0 (50.0) .34
Abbreviations: IQR, interquartile range; SD, standard deviation; SF-36, 36-Item Short Form Health Survey.
* Higher scores are indicative of better health status. Data are presented as mean ± SD and median (25%-75% IQR). The SF-36 results are usu-
ally reported as mean ± SD; however, the distribution of many of the domains are nonnormal. P values are reported for each analysis method 
(parametric vs nonparametric) showing that no significant values resulted from using either method. Some data are unavailable for each domain 
analysis.
†A P value <0.05 was considered statistically significant
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Tavakol and Dennick, if a test has more than one concept, like the SF-36, it may 
not make sense to report Cronbach’s alpha for the test as a whole, as the larger 
number of questions will decidedly inflate the value of Cronbach’s alpha (14). 
Tavakol and Dennick recommend reporting Cronbach’s alpha for each of the 
domains separately rather than for the entire test.
Fig. 2. Mean scores for the 8 domains of  the SF-36 in patients treated with low- vs high-dose 
opioids for non-cancer pain (n = 182).
Fig. 3. General health perceptions in patients treated with low- vs high-dose opioids for 
non-cancer pain. 
Table 6 reports Cronbach’s 
alpha for the 8 domains mea-
sured by the SF-36. Of the 8 
domains of the SF-36, only 
the Social Functioning domain 
was considered unreliable; all 
other domains had α > .70. The 
Social Functioning domain, 
which is based on 2 questions, 
is a measure of limitations 
in social activities because of 
physical or emotional prob-
lems. The alpha coefficient for 
the Social Functioning domain 
was less reliable in the low-
dose opioid treatment group 
at .533 (n = 92) compared with 
the alpha coefficient of .622 (n 
= 84) in the high-dose group.
discussion
There is increasing con-
cern about the risks of and 
negative side effects of opioid 
medications. These concerns 
are heightened for patients 
who are prescribed high doses 
of opioids. We examined the 
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patients with CNCP who were prescribed daily opioid 
doses of greater than 90 MME, relative to patients pre-
scribed low-opioid doses, to attempt to better under-
stand the social and functional implications of chronic 
opioid treatment. 
It was interesting to note that the patients receiv-
ing high-dose opioids tended to have a poorer percep-
tion of health as well as significantly increased reported 
side effects, increased rates of unemployment, and 
increased rates of noncompliance. Among the high-
dose opioid patients, disability was significantly more 
likely to be listed as the reason for unemployment, 
compared to retirement among patients receiving low-
dose opioids. It is important to differentiate between 
retirement and disability as the reason for a patient’s 
unemployment. This is because if a patient retires, that 
means the patient was able to voluntarily quit working. 
On the other hand, if the reason is disability, it means 
that the patient may have had to stop employment pre-
maturely despite their desire to work, which may lead 
to a lower quality of life. In addition, disability may un-
derlie a more severe pathology or pain, as it restricted 
them from working. It is not entirely clear whether or 
not the high-dose opioid patients suffered from worse 
pain or underlying pathology or functional impair-
ment, but the 2 opioid treatment groups did not differ 
significantly with respect to baseline characteristics of 
age, BMI, gender, or 6 common categories of diagnosis. 
The relationships between lower versus higher doses of 
opioid treatment and level of pain reduction, amount 
of functional improvement, as well as any improvement 
in a patient’s physical and emotional health are com-
plex and nonlinear. The results of this study indicate 
that low-dose opioid patients tend to do significantly 
better than high-dose opioid patients with respect to 
fewer reported side effects, lower incidence of non-
compliance, and higher rates of employment. Given 
the significant risks of opioids – especially at higher dos-
ages – including concerns about possible hyperalgesia, 
and given no statistically significant improvements over 
low-dose opioid treatment in regard to physical and 
emotional health parameters, it is reasonable to con-
clude that high-dose opioid treatment for CNCP should 
be avoided whenever possible.
There are some limitations to this study. First, its ob-
servational design prohibits drawing causal relationships 
between the use of opioid treatment for non-cancer 
pain and quality of life. Another limitation is that there 
were restricted entry criteria into the study: chronic non-
cancer pain patients presenting at the West Penn Pain 
Institute between the ages of 18 to 80 who did not have 
a concurrent cancer diagnosis and who were not receiv-
ing end-of-life care. Also, the study population was one 
of convenience. The study population included patients 
who were receiving opioid treatment at a single facil-
ity (large urban teaching hospital and Level 1 trauma 
center), which may limit the generalizability of the 
findings. Another limitation is that the SF-36 was only 
given post-opioid treatment. The lack of a baseline SF-36 
measure prevented us from quantitatively determining 
how opioid treatment for non-cancer pain changed the 
patients’ SF-36 scores post treatment.
Another limitation in this retrospective cohort 
study is that it only provides a single snapshot view of 
a patient’s perception of their current quality of life in 
relation to their current pain regimen. In order to draw 
conclusions about a patient’s change in quality of life, 
we would need to collect more information about the 
patient’s baseline level of pain or pathology, previous 
perception about their quality of life, and previous 
pain regimen. For instance, it could be that patients on 
high-dose chronic opioid therapy have failed low-dose 
therapy and have had to escalate to a higher dose. 
Alternatively, it could be that patients on high-dose 
opioid therapy may have had more severe pathology 
or pain at the start of treatment. It would be interest-
ing to do a longitudinal study incorporating the points 
above to examine a temporal relationship between opi-
oid dosage and quality of life. Also, patients enrolled in 
the study had non-cancer pain associated with differ-
ent conditions as well as different prognoses, thereby 
raising the possibility of selection bias. Selection bias 
can often result in patients having less favorable out-
comes in one group compared to another group (15). 
Self-reported data may not always be reliable. Cook 
and Campbell have pointed out that subjects (a) choose 
to report what they believe the researcher expects 
to see; or (b) report what reflects them in a positive 
light in terms of their abilities, knowledge, beliefs, or 
opinions (16). Another concern about such data centers 
on whether subjects are able to accurately recall past 
behaviors. 
A further drawback was the absence of data on 
prior pain treatments, alcohol use, illegal drug use, 
patient preference for treatment with low- versus high-
dose opioids, patient socioeconomic status, concurrent 
benzodiazepine usage, psychiatric conditions, and edu-
cation level. These variables may be factors affecting 
the SF-36 scores of patients irrespective of their treat-
ment of non-cancer pain with opioids. It would be in-
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teresting to look at treatment with benzodiazepines, in 
particular, for future studies. Concurrent prescriptions 
of benzodiazepines can be problematic, as sedative-
hypnotic medications may interact with opioids to in-
crease the likelihood of adverse events, and non-opioid 
pain medications are often recommended as one part 
of a comprehensive pain management program to help 
enhance pain control. It has been shown that polyphar-
macy with benzodiazepines may lead to higher risk of 
aberrant behavior, adverse events including respiratory 
depression, and overdose (17). Patients’ socioeconomic 
status and concurrent psychiatric conditions would have 
provided further insight as well. Low socioeconomic 
status and psychiatric comorbidities may be predictive 
of aberrant behaviors and are characteristics identified 
in risk screening tools for prescribing opioids (18).
conclusion
The SF-36 is a reliable measure of the physical and 
emotional dimensions of health, specifically a patient’s 
functional health, well-being, psychometrically-based 
physical health, and mental health. The study also ana-
lyzed patients’ employment status, reasons for unem-
ployment, pain diagnosis, side effects, and compliance 
issues through the electronic medical record.
Data analysis suggests that low-dose and high-dose 
opioid treatment patients do not have significantly dif-
ferent quality-of-life outcomes. 
Patients receiving high-dose opioid treatment 
tended to have a poorer perception of health as well 
as significantly increased report of side effects, in-
creased rates of unemployment, and increased rates of 
noncompliance. Among the high-dose opioid patients, 
disability was significantly more likely to be listed as 
the reason for unemployment, as opposed to retire-
ment for patients receiving low-dose opioids. Although 
it is not entirely clear whether or not the high-dose 
opioid patients suffered from worse pain or underlying 
pathology or functional impairment, the 2 opioid treat-
ment groups did not differ significantly with respect to 
baseline characteristics of age, BMI, gender, or 6 com-
mon diagnosis categories. 
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